UK's First MS Patient Receives CAR T-Cell Therapy
A UK woman with Multiple Sclerosis (MS) has become the first in the country to receive CAR T-cell therapy as part of a trial at University College London Hospitals NHS Foundation Trust (UCLH).
The innovative treatment, initially developed for cancer, reprograms a patient's own immune cells to target the B-cells driving MS, offering hope that a single infusion may one day stop relapses and irreversible nerve damage.
Multiple sclerosis (MS) affects the central nervous system, including the brain and spinal cord, causing symptoms such as blurred vision and problems with movement, memory, and thinking due to damaged myelin that protects nerves.
The treatment offers hope that a single infusion may one day stop relapses and irreversible nerve damage.
Author's summary: CAR T-cell therapy breaks new ground in treating MS.
More News
- Binance & AAVE Show Signs of Slowdown While BlockDAG Climbs to $432M+ & Prepares For Genesis Day
- AI cyber attacks: The Halloween edition
- Tackling youth vaping: Current regulations fall short and new tech offers effective solutions
- BlockDAG’s $0.0015 TGE Code Offers VIP Early Access, Outshining Ozak AI and Avalon X Presales
- Thousands of international students' scholarship contracts to be tightened after ELTE scandal
- The Sundarbans: Our shield against climate change
- The price of going cashless
- In response to ‘The DMV: Humanity’s greatest crime against itself’
- Council facing £40m budget gap next year as officers warn savings need to be found